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Abstract: The objectives of this study were to determine the main characteristics associated with
the presence of heart failure (HF) in patients with type 2 diabetes (T2DM), and specifically to
assess the association of the risk classification proposed by the Kidney Disease Improving Global
Outcomes (KDIGO) guidelines with HF. The DIABET-IC study is a multicentre, observational,
prospective and analytical study in T2DM patients recruited in Spanish hospitals. This work,
which features a cross-sectional design, has been conducted with the data obtained at the inclusion
visit. The main dependent variable analysed was the presence of HF. The predictive variables
evaluated were the demography, clinic, laboratory testing (including natriuretic peptides) and
echocardiography. Patients were classified according to the number of vascular territories with
atherosclerotic involvement and the KDIGO risk category. Multivariate logistic regression models
were performed to determine the risk posed by the various baseline variables to present HF at the
time of study inclusion. The study included 1517 patients from 58 hospitals, with a mean age of
67.3 (standard deviation (SD): 10) years, out of which 33% were women. The mean DM duration
was 14 (SD: 11) years. The prevalence of HF was 37%. In a multivariate analysis, the independent
predictors of HF were increased age (odds ratio (OR) per 1 year = 1.02; p = 0.006), decreased systolic
blood pressure (OR per 1 mmHg = 0.98; p < 0.001), decreased haemoglobin (OR per 1 g/dL = 0.86;
p < 0.001), the presence of obstructive sleep apnoea (OR = 1.61; p = 0.006), the absence of hepatic
steatosis (OR = 0.59; p = 0.016), the severity of atherosclerotic involvement (OR 1 territory = 1.38
and OR > 1 territory = 2.39; p = 0.02 and p < 0.001 respectively) and the KDIGO risk classification
(high-risk OR = 2.46 and very high-risk OR = 3.39; p < 0.001 for both). The KDIGO risk classification
is useful to screen for the presence of HF in T2DM patients. Therefore, we believe that it is necessary
to carry out a systematic screening for HF in the high- and very high-risk KDIGO categories.
Keywords: type 2 diabetes; cardiovascular disease; heart failure; KDIGO risk category
1. Introduction
It is widely known that patients with diabetes have an increased risk of cardiovascular
disease (CVD) [1]. The presence of diabetes mellitus increases the risk of heart failure (HF)
by more than 50%. At present, HF is the second most frequent manifestation of CVD in
patients with type 2 diabetes mellitus (T2DM) [2]. In a large population-based study, the
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most important risk factors identified for HF hospitalization in T2DM patients were atrial
fibrillation, excess body weight and the loss of renal function [3]. In fact, despite having
HbA1c levels, blood pressure, LDL-cholesterol and urinary albumin excretion within the
recommended targets, the increased risk given by T2DM is not completely neutralised.
Pathophysiologically, the increased risk of HF in T2DM patients can be attributed to
the presence of ischemic heart disease (myocardial infarction being a main cause of HF
with reduced ejection fraction), high blood pressure and the presence of a specific diabetic
cardiomyopathy [4]. Insulin resistance, hyperglycaemia, myocardial lipotoxicity with
mitochondrial dysfunction and oxidative stress, and the inflammatory response lead to
myocardial fibrosis and diastolic dysfunction [5]. Myocardial microvascular dysfunction is
considered to play a key role in the development of HF with preserved ejection fraction [6].
The development of diabetic chronic kidney disease (CKD) is an additional factor that
increases the likelihood of HF, mainly because it facilitates the development of atheroscle-
rotic lesions, fibrosis, left ventricular hypertrophy and valvular calcifications [7]. The 2012
Guidelines of the Kidney Disease Improving Global Outcomes (KDIGO) [8] define four
risk categories for the combined prognosis of total mortality, cardiovascular mortality and
events related to the flare-up and progression of CKD, but do not specifically mention its
importance as a predictive factor of HF.
Treatment with SGLT2 inhibitors has been associated with reduced risk of HF. Cur-
rently, all guidelines recommend the use of SGLT2 inhibitors in the presence of HF, es-
pecially with reduced ejection fraction [9,10]. Since HF in T2DM patients is a frequent
and clinically relevant condition that can be improved with specific treatments, its early
detection is essential [11].
Recent international guidelines acknowledge the relevance of HF in DM patients and
recommend atrial fibrillation screening [12]. However, beyond the clinical suspicion and
classical risk factors monitoring [13], they do not establish specific recommendations on
the need to determine natriuretic peptides or perform an echocardiogram.
Our hypothesis was that the probability of a T2DM patient having HF could be
predicted from the existence or absence of easily identifiable clinical risk conditions. After
natriuretic peptide-based screening, the performance of specific tests (echocardiogram)
could confirm the diagnosis and lead to an appropriate treatment.
Our objective, based on the baseline data from the DIABET-IC study (Spanish mul-
ticentre study on the prevalence and incidence of heart failure in patients with type 2
diabetes in hospital consultation rooms throughout the country), was to determine the
main characteristics associated with the risk of presenting HF, with a special focus on
evaluating the usefulness of the risk classification proposed by the KDIGO guidelines.
2. Material and Methods
2.1. Design
The DIABET-IC study is a multicentre, observational, prospective and analytical study
conducted in Spanish hospitals promoted by the Spanish Society of Diabetes (SED) and
the Spanish Society of Cardiology (SEC). It has an observational, pragmatic design, with a
follow-up of patients under conditions of routine clinical practice. After the initial visit,
the planned follow-up was 3 years. The study was conducted in accordance with the
Declaration of Helsinki, and it was approved by the Ethics Committee of Toledo Hospital
Complex on 28 March 2018 (project identification code 243). All patients signed an informed
consent to participate.
This work, with a cross-sectional design, has been conducted with the data obtained
from patients in the inclusion visit between 2018 and 2019.
2.2. Patients
The inclusion criteria were patients aged 18 years or older, with type 2 diabetes
diagnosed at least 1 year before the study start according to the Criteria of the American
Diabetes Association (ADA) in force at that time [14]. Patients with type 1 diabetes, with
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the presence of stage 5 chronic kidney disease or with an estimated life expectancy of less
than 3 years due to neoplasms or other serious systemic diseases were excluded.
The subjects were to be seen in external endocrinology and/or cardiology consulta-
tion rooms. Each participating centre could include a maximum of 40 patients (20 from
endocrinology and 20 from cardiology units). Recruitment was consecutive to avoid
selection bias.
The expected sample size was 2400 patients distributed in 60 centres. This sample
size, with a confidence level of 95%, would allow the estimation of the incidence of HF
for 3 years with an absolute accuracy of 0.6%. However, due to recruitment problems, the
desired number of patients was not reached.
2.3. Primary Dependent Variable
The main dependent variable analysed was the presence of HF at the inclusion visit.
The definition of HF was collected in the guidelines of the European Society of Cardiology
(ESC) [15] in 2016. HF was classified as HF with reduced ejection fraction (HFrEF) if the left
ventricular ejection fraction (EF) was less than 40%. Due to the limited number of patients,
all those with EF greater than or equal to 40% were considered subjects with preserved EF
(HFpEF). In a sensitivity analysis, an EF cut-off point of 50% was selected for the definition
of HFpEF.
2.4. Variables Obtained at Inclusion
Demographic data (age, sex), lifestyle (smoking status, alcohol consumption) and
concomitant pathologies: coronary artery disease (CAD), defined as a history of acute my-
ocardial infarction, revascularization or coronary stenosis > 50%; cerebrovascular disease
(CD), defined as a history of stroke or carotid stenosis > 50%; peripheral artery disease
(PAD), defined as lower limb artery disease; atherosclerotic cardiovascular disease (ACVD),
defined as CAD and/or CD and/or PAD, with classification of the number of affected
territories into 3 categories (none, one, or more than one); chronic obstructive pulmonary
disease (COPD); obstructive sleep apnoea syndrome (OSA); high blood pressure (HBP),
defined as blood pressure > 140/90 mmHg or taking hypotensive drugs; atrial fibrillation
(AF); fatty liver disease (FLD); and finally the Charlson score.
Data related to T2DM: disease duration; result of the ocular fundus examination,
classifying the findings as normal, simple retinopathy or proliferative retinopathy; pres-
ence of neuropathy by clinical diagnosis; presence of nephropathy, defined as glomeru-
lar filtration rate (GFR) < 60 mL/min/1.73 m2 and/or urinary albumin excretion rate
(UAER) ≥ 30 mg/g.
Physical examination: weight and height measurements in light clothing and without
footwear, with estimation of body mass index (BMI) in the form of weight (Kg)/height
(m)2; measurement of systolic and diastolic blood pressure, with the patient seated, after at
least 5 min of rest, and with a cuff appropriate to the circumference of the arm.
Fasting blood sample collection to measure: glycaemia (mg/dL); HbA1c (%); lipid pro-
file (total cholesterol, triglycerides, HDL-cholesterol), with non-HDL cholesterol (NHDLC)
calculation (total cholesterol—HDL) expressed in mg/dL; creatinine (mg/dL), with deter-
mination of GFR using the CKD-EPI formula; UAER in a morning urine sample, expressed
in mg/g of creatinine; haemoglobin (g/dL); natriuretic peptides (BNP or NT-proBNP)
expressed in pg/mL. Measurements were made in each participating hospital following
routine procedures.
Electrocardiogram, with rhythm assessment.
Echocardiogram, with measurement of left ventricular ejection fraction (LVEF). The
procedure was conducted in each of the participating centres, and patients were classified
in 3 categories: preserved (≥50%), intermediate (40–49%) and reduced (<40%), with
subsequent recoding into 2 categories: preserved (≥40%) or reduced (<40%).
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Patients were also classified based on their GFR (expressed in mL/min/1.73 m2) and
UAER (expressed in mg/g of creatinine) in 4 risk categories, following the indications of
the KDIGO guideline [8]:
Low risk: GFR ≥ 60 and UAER < 30.
Moderate risk: GFR ≥ 60 and UAER 30–300 or GFR 45–59 and UAER < 30.
High risk: GFR ≥ 60 and UAER > 300 or GFR 45-59 and UAER 30–300 or GFR 30–44
and UAER < 30.
Very high risk: GFR 45–59 and UAER > 300 or GFR 30–44 and UAER ≥ 30 or GFR < 30.
2.5. Statistical Methods
The quantitative variables were described with their mean and standard deviation (SD)
or as median with interquartile range. Qualitative variables were expressed as frequency
distribution in %.
A comparison of quantitative variables was made with the student’s t test on inde-
pendent samples or ANOVA, or with non-parametric tests if the assumptions of normality
were violated. The comparison of qualitative variables was done with X2 test.
Logistic regression models were performed to determine the risk conferred by the
different variables to show HF at the time of study inclusion, calculating the odds ratio (OR)
with its 95% confidence interval (CI). Univariate and multivariate analyses were performed.
The criteria for the inclusion of the variables in the models were based on their significance
in the univariate analysis (p < 0.05) or on their clinical meaning. Highly correlated variables
were not included simultaneously.
The initial multivariate model included age, sex, COPD, smoking status, HBP (or
alternatively systolic and diastolic blood pressure), NHDLC, BMI, OSA, FLD, T2DM
duration, presence of retinopathy, HbA1c, haemoglobin, KDIGO risk classification, (or
alternatively GFR and UAER), AF, CAD, CD and PAD (or alternatively the number of
vascular territories affected). The values of natriuretic peptide tests were not included
because they were involved in the diagnostic process. Finally, a sequential exclusion
procedure was performed to obtain the independent risk factors of presenting HF.
In a sensitivity analysis, we included in the multivariate models a variable named
“origin of the patients.”
Associations with a p < 0.05 were considered significant.
3. Results
A total of 1517 patients from 58 Spanish hospitals were included, with a mean age of
67.3 (SD 10) years, of which 33% were women. The mean T2DM duration was 14 (SD 11)
years, with 42.6% of patients receiving insulin treatment. The proportion of patients with
chronic complications was: 12.5% retinopathy (7.6% simple and 4.9% proliferative), 30.3%
nephropathy, 5.6% neuropathy and 49% ACVD (38.2% with an affected territory and 10.8%
with more than one affected territory). Regarding the KDIGO risk categories, 56.3% of the
patients were low risk, 23.3% moderate, 12% high and 8.4% very high.
The proportion of patients with protective cardiovascular treatments was high: 40.5%
on SGLT2 inhibitors, 16.5% on GLP1 receptor agonists, 68.6% on ACEI or ARB, 58.5% on
beta-blockers, 21.2% on mineralocorticoid receptor antagonists, 11% on sacubitril-valsartan,
84% on statins, 0.9% on PCSK9 inhibitors, 52.7% on antiplatelet agents and 25.7% on oral
anticoagulants.
Valid data were obtained for the HF classification in 1497 patients. The prevalence of
HF was 37% (16% EF < 40%; 8% EF 40-49%; 13% EF ≥ 50%). The prevalence of HF increased
statistically significantly in patients with OSA, in patients with AF, in the presence of ACVD
(especially in patients with PAD and as the number of affected territories increased) and
in the successive risk categories according to the KDIGO classification (Figure 1). The
prevalence was higher than 50% in subjects with AF (66.7%), in the KDIGO very high-risk
category (66%), with an atherosclerotic involvement of more than 1 vascular territory
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(56.7%) and with the presence of PAD (52.4%). The Supplementary Figure S1 shows the
prevalence of HF with EF < 40% and ≥40% separately.
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Cerebrovascular disease (%) 128 (8.5) 66 (7) 62 (11.2) <0.001 1.67 1.16–2.41 
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Figure 1. Prevalence of HF based on the patients’ concomitant conditions (OSA: obstructive sleep apnoea syndrome; CAD:
coronary artery disease; CD: cerebrovascular disease; PAD: peripheral artery disease; ACVD: atherosclerotic cardiovascular
disease; AF: atrial fibrillation; KDIGO: Kidney Disease Improving Global Outcomes).
As expected, the prevalence of HF was higher in patients coming from the cardiology
units than in those coming from the endocrinology units (51.6% vs 16%; p < 0.001). The
distribution of patients with EF < 40% and ≥40% was different between both units: 25.1%
and 26.5%, respectively, in cardiology vs 2.9% and 13.1%, respectively, in endocrinology
(p < 0.001). There was also a higher proportion of patients with ACVD (61.2% vs 31.7%;
p < 0.001) in the cardiology sample.
Table 1 compares the patie ts’ ch racteristics based on whether they had HF at baseline.
Patients with HF were older; had a higher prevalence of COPD, OSA, ACVD and AF; and
a lower prevalence of FLD. They also had lower blood pressure and lower NHDLC,
haemoglobin and GFR levels, but higher values of UAER and NT-proBNP. Interestingly,
patients with HF were characterized by having a greater number of vascular territories
affected by atherosclerosis, and a higher proportion of subjects were in the KDIGO high-
and very high-risk categories. Table 2 further compares the patients with HF depending on
whether their EF is less than 40%. The Supplementary Table S1 uses the alternative cut-off
point f 50%.
In the multivariate analyses, the ind pendent pr dictors of the pr sence of HF (Table 3)
were increased age (OR per 1 year 1.02; p = 0.006), decreased systolic blood pressure (OR
per 1 mmHg = 0.98; p < 0.001) and haemoglobin (OR per 1 g/dL = 0.86; p < 0.001), the
presence of OSA (OR = 1.61; p = 0.006), KDIGO risk classification (high-risk OR = 2.46 and
very high-risk OR = 3.39; p < 0.001 both) and the presence of ACVD (OR 1 territory = 1.38
and OR more than one territory = 2.39; p = 0.02 and p < 0.001 respectively). Conversely, the
presence of FLD was a protective f ctor in the limit of statistical significance (OR = 0.59;
p = 0.016). The statistical significance of FLD was lost after adjusting for origin of the
patients (OR = 0.83; p = 0.41).
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Table 1. Patients’ baseline characteristics and univariate OR for the risk of having HF.




n = 554 p OR 95% CI
Age (years) 67.3 (10.1) 65.9 (9.9) 69.8 (9,9) <0.001 1.04 1.03–1.05
Gender (% female) 501 (33) 320 (33.9) 169 (30.5) 0.17 0.86 0.68–1.07
Current smoking (%) 164 (10.8) 116 (12.3) 46 (8.3) 0.12 0.74 0.51–1.08
Hypertension (%) 1244 (81.9) 763 (80.9) 466 (84.1) 0.12 1.25 0.94–1.65
Chronic obstructive pulmonary
disease (%) 166 (10.9) 79 (8.4) 85 (15.3) <0.001 1.98 1.43–2.75
Obstructive sleep apnoea (%) 232 (15.3) 126 (13.4) 102 (18.4) 0.009 1.46 1.10–1.95
Fatty liver disease (%) 181 (12.1) 132 (14.2) 43 (7.8) <0.001 0.51 0.35–0.73
Auricular fibrillation (%) 327 (21.6) 108 (11.4) 217 (39.2) <0.001 4.98 3.83–6.48
Coronary artery disease (%) 633 (41.9) 339 (36) 291 (52.5) <0.001 1.97 1.59–2.44
Cerebrovascular disease (%) 128 (8.5) 66 (7) 62 (11.2) <0.001 1.67 1.16–2.41
Peripheral artery disease (%) 164 (10.8) 78 (8.3) 86 (15.5) <0.001 2.04 1.47–2.82
Atherosclerotic cardiovascular





0 (%) 771 (51) 537 (57) 222 (40.1)
<0.001
1 -
1 (%) 577 (38.2) 335 (35.5) 239 (43.1) 1.73 1.37–2.17
>1 (%) 164 (10.8) 71 (7.5) 93 (16.8) 3.17 2.24–4.48
Charlson index (points) 0.62 (0.88) 0.52 (0.8) 0,81 (0.98) <0.001 1.44 1.28–1.62
Retinopathy




(%) 74 (4.9) 45 (4.8) 29 (5.2) 1.07 0.66–1.72
Body mass index (Kg/m2) 30.3 (5.2) 30.3 (5.1) 30.1 (5.4) 0.57 1.00 0.98–1.02
Systolic blood pressure (mmHg) 135 (19.4) 138 (18) 129 (21) <0.001 0.98 0.97–0.98
Diastolic blood pressure (mmHg) 76 (11.5) 77 (11) 73 (11) <0.001 0.96 0.95–0.97
Diabetes duration (years) 14 (11.1) 13.7 (9.9) 14.7 (12.9) 0.14 1.01 1.00–1.02
HbA1c (%) 7.3 (1.3) 7.3 (1.3) 7.2 (1.3) 0.12 0.94 0.86–1.02
Non-HDL cholesterol (mg/dL) 109 (34.1) 110 (34) 107 (35) 0.04 0.99 0.99–1.00
Triglycerides (mg/dL) * 133 (85) 129 (87) 136 (82) 0.55 1.00 0.99–1.00
Haemoglobin (g/dL) 14 (1.8) 14.3 (1.7) 13.6 (1.9) <0.001 0.82 0.77–0.87
NT-proBNP (pg/mL) * 243 (782) 127 (245) 851 (1958) <0.001 1.001 1.000–1.002
Glomerular filtration rate
(mL/min/1.73 m2) 73.1 (22.7) 77.9(20.8) 64.6 (23.5) <0.001 0.97 0.96–0.98
Urinary albumin excretion
(mg/g) 87 (393) 62 (201) 132 (603) 0.017 1.001 1.000–1.001
KDIGO risk
Low (%) 715 (56.4) 518 (63.6) 194 (43)
<0.001
1 -
Moderate (%) 295 (23.3) 190 (23.4) 105 (23.3) 1.48 1.10–1.97
High (%) 152 (12) 70 (8.6) 82 (18.2) 3.13 2.18–4.48
Very high (%) 106 (8.4) 36 (4.4) 70 (15.5) 5.19 3.36–8.02
The values in the boxes are the number of patients (%), mean (standard deviation) or median * (interquartile range). OR: odds ratio; CI:
confidence interval; HbA1c: glycated haemoglobin; HDL: High-density lipoprotein; NT-proBNP: N-terminal fragment of brain natriuretic
peptide; KDIGO: Kidney Disease Improving Global Outcomes.
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Table 2. Patients’ baseline characteristics based on the type of HF.





with EF < 40%
n = 240
Group 3: HF
with EF ≥ 40%
n = 314
p p Group 2vs 3
Age (years) 67.3 (10.1) 65.9 (9.9) 68.1 (9.9) 71.1 (9.7) <0.001 <0.001
Gender (% female) 501 (33) 320 (33.9) 52 (21.7) 117 (37.2) <0.001 <0.001
Current smoking (%) 164 (10.8) 116 (12.3) 27 (11.2) 19 (6.1) <0.001 0.017
Hypertension (%) 1244 (81.9) 763 (80.9) 188 (78.3) 278 (88.5) 0.002 0.001
Chronic obstructive
pulmonary disease (%) 166 (10.9) 79 (8.4) 39 (16.2) 46 (14.6) <0.001 0.60
Obstructive sleep apnoea (%) 232 (15.3) 126 (13.4) 37 (15.4) 65 (20.7) 0.007 0.11
Fatty liver disease (%) 181 (12.1) 132 (14.2) 14 (5.9) 29 (9.3) <0.001 0.14
Auricular fibrillation (%) 327 (21.6) 108 (11.4) 92 (38.3) 125 (39.8) <0.001 0.72
Coronary artery disease (%) 633 (41.9) 339 (36) 148 (61.6) 143 (45.5) <0.001 <0.001
Cerebrovascular disease (%) 128 (8.5) 66 (7) 28 (11.7) 34 (10.8) 0.019 0.76
Peripheral artery disease (%) 164 (10.8) 78 (8.3) 37 (15.4) 49 (15.6) <0.001 0.95
Atherosclerotic cardiovascular





0 771 (51) 537 (57) 76 (31.7) 146 (46.5)
<0.001 0.0021 577 (38.2) 335 (35.5) 120 (50) 119 (37.9)
>1 164 (10.8) 71 (7.5) 44 (18.3) 49 (15.6)
Charlson index (points) 0.62 (0.88) 0.52 (0.8) 0.78 (0.95) 0.83 (1.00) <0.001 0.50
Retinopathy
Simple (%) 114 (7.6) 77 (8.2) 14 (5.8) 18 (5.7)
0.64 0.88Proliferative
(%) 74 (4.9) 45 (4.8) 13 (5.4) 16 (5.1)
Body mass index (Kg/m2) 30.3 (5.2) 30.3 (5.1) 29.4 (5.3) 30.7 (5.4) 0.012 0.005
Systolic blood pressure
(mmHg) 135 (19.4) 138 (18) 126 (19.8) 132 (19.8) <0.001 <0.001
Diastolic blood pressure
(mmHg) 76 (11.5) 77 (11) 72 (11.8) 73 (11.2) <0.001 0.10
Diabetes duration (years) 14 (11.1) 13.7 (9.9) 15.4 (15.3) 14.1 (10.7) 0.1 0.46
HbA1c (%) 7.3 (1.3) 7.3 (1.3) 7.2 (1.2) 7.3 (1.3) 0.26 0.58
Non-HDL cholesterol
(mg/dL) 109 (34.1) 110 (34) 104 (34) 109 (35) 0.026 0.09
Triglycerides (mg/dL) * 133 (85) 129 (87) 134 (82) 138 (84) 0.33 0.16
Haemoglobin (g/dL) 14 (1.8) 14.3 (1.7) 13.9 (1.9) 13.4 (1.8) <0.001 0.004
NT-proBNP (pg/mL) * 243 (782) 127 (245) 1089(2661) 627 (1563) <0.001 0.038
Ejection Fraction (%) 54.9 (13.4) 61.5 (7.6) 32.8 (7.9) 54 (10.4) <0.001 <0.001
Glomerular filtration rate
(mL/min/1.73 m2) 73.1 (22.7) 77.9 (20.8) 66.3 (23.1) 66.3 (23.8) <0.001 0.14
Urinary albumin excretion
(mg/g) 87 (393) 62 (201) 165 (825) 112 (404) 0.004 0.36
KDIGO risk
Low (%) 715 (56.4) 518 (63.6) 73 (41.7) 121 (43.8)
<0.001 0.97
Moderate (%) 295 (23.3) 190 (23.4) 42 (24) 63 (22.8)
High (%) 152 (12) 70 (8.6) 33 (18.9) 49 (17.7)
Very high (%) 106 (8.4) 36 (4.4) 27 (15.4) 43 (15.6)
The values in the boxes are the number of patients (%), mean (standard deviation) or median * (interquartile range).
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Table 3. Independent variables (multivariate analysis) associated with the risk of HF at the inclu-
sion visit.
Variable OR 95% CI p
Age (years) 1.02 1.01–1.03 0.006
Obstructive sleep apnoea 1.61 1.14–2.25 0.006
Fatty liver disease 0.59 0.39–0.91 0.016
Coronary artery disease 1.66 1.31–2.11 <0.001




1 1.38 1.05–1.81 0.02
>1 2.39 1.59–3.60 <0.001
Systolic blood pressure (mmHg) 0.98 0.97–0.99 <0.001
Haemoglobin (g/dL) 0.86 0.80–0.93 <0.001
Glomerular filtration rate (mL/min/1.73 m2) 0.976 0.97–0.98 <0.001
KDIGO risk
Low 1 -
Moderate 1.26 0.93–1.72 0.14
High 2.46 1.67–3.64 <0.001
Very high 3.39 2.09–5.48 <0.001
Figure 2 shows the distribution of patients and the adjusted OR for the prevalence of
HF in the four KDIGO risk categories.
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categories; OR: odds ratio.
4. Discussion
In our work, conducted in a patient sample with T2DM coming from outpatient
cardiology and endocrinology units, with a prevalence of HF of 37%, we found that the
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main clinical conditions independently associated with the presence of HF were age, the
presence of OSA, atherosclerotic CVD and renal involvement.
The prevalence of HF has increased in recent years, justified by the aging of the
population and better survival after diagnosis [16]. T2DM and HF often coexist, and each
disease increases the risk of the onset of the other [17]. In a meta-analysis of 31 studies with
more than 41,000 patients, the prevalence of T2DM in patients with HF was 23%, similar to
the prevalence in patients with preserved or reduced EF [18].
Similarly, in a meta-analysis of cardiovascular safety trials in patients with T2DM,
the prevalence of HF has been detected to be between 9% and 28%, although without
systematic performance of natriuretic peptide tests or echocardiogram [19]. The prevalence
obtained in our study, 37%, should be interpreted considering the origin of the patients and
the performance of systematic screening. Although the sample derived from the cardiology
units would be clearly biased toward obtaining high values, the prevalence of 16% obtained
in patients recruited in the endocrinology units may be valid for subjects in the sixth decade
of life and with a duration of the disease greater than 10 years. The higher proportion of
HFrEF in cardiology patients can be justified by their greater presence of ACVD.
On the other hand, the number of comorbidities associated with the presence of HF has
been described as high [16], ranging from 3.4 in 2002 to 5.4 in 2014. In our study, patients
with HF, in addition to T2DM, had a higher prevalence of HBP (although with lower
systolic blood pressure, especially in the case of HFrEF, justified by the greater intensity of
pharmacological treatment and/or deterioration of ventricular function), COPD, OSA, AF,
atherosclerotic vascular involvement in any vascular territory and renal impairment.
Patients with OSA are characterized by higher blood pressure, insulin resistance and
activity of the sympathetic nervous system, which favours the appearance of arrhythmias
and HF [20]. In addition, they also have a higher prevalence of visceral obesity, which has
harmful effects on the myocardium, favouring inflammation, fibrosis and the development
of two strongly related pathologies, AF and HFpEF [21]. In our study, the presence of OSA
increased the prevalence of HF by approximately 50% and the presence of AF increased
risk by almost a factor of 5, although this association was not statistically significant in the
multivariate analysis.
PAD is the manifestation of ACVD most strongly associated with DM, and its presence
may increase the risk of major cardiovascular events (MACE) even more than CAD [22]
itself. In the DECLARE [23] study, patients with PAD had a higher prevalence of HF and a
higher incidence of hospitalization for HF. More importantly, in both the FOURIER [24] and
EMPA-REG OUTCOME [25] studies, the atherosclerotic involvement of multiple vascular
territories has been shown to increase the risk of MACE and HF more than that of a single
one. In our work, we found that the involvement of more than 1 vascular territory doubled
the prevalence of HF.
The last aspect, and probably the most important, was that we found a great impact
of the KDIGO risk classification (high- and very high-risk levels) on the prevalence of HF.
This finding is biologically plausible [7], and has been supported by the observation that,
in cardiovascular safety studies in type 2 diabetes enriched with patients with CKD, the
incidence of HF hospitalization exceeds that of ACVD [19]. In a secondary analysis of the
CANVAS [26] study, there was also an increase in the prevalence of HF and in the incidence
rate of hospitalization for HF in the successive KDIGO risk categories, with the beneficial
effect of canagliflozin being more marked in absolute terms in the highest risk categories.
Given the association between HF and CKD, the KDIGO guidelines recommend developing
strategies to diagnose and treat both conditions at an early stage [27]. Importantly, the
additive effect of polyvascular disease and CKD found in our study on HF risk has also
been confirmed in other populations [25]. Our additional finding that haemoglobin was a
protective factor can be justified by its close relationship with renal function.
It was surprising to find a lower prevalence of FLD in patients with HF, since the
association between hepatic fibrosis and diastolic dysfunction has been described [28].
However, in our sample, no imaging tests or biomarker panels were systematically per-
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formed, so the collected prevalence of FLD (12.1%) was much lower than that described [29]
in patients with T2DM, up to 70%. Furthermore, the statistical significance of FLD was lost
after adjusting for the origin of the patients.
As the strengths of our work, we highlight the recruitment of a large sample of T2DM
patients, the systematic performance of natriuretic peptide tests and echocardiograms to
accurately diagnose the prevalence of HF, and the collection of multiple demographics,
clinical and analytical variables to evaluate factors associated with the presence of HF. As
for the weaknesses, it should be noted that the origin of the patients implies a selection
bias, that the desired sample size was not reached due to recruitment problems, that the
cross-sectional design did not allow the establishment of the causal effect of the associations
found and that the multicentre design did not allow the standardization of biochemical
and echocardiographic measurements. In fact, the associations of FLD and lower blood
pressures with HF may be related to which clinic the diabetes patients came from and not
potential etiologic associations.
In conclusion, we found that the KDIGO risk classification (high- and very high-risk
categories), the presence of OSA and the existence of ACVD (especially in the case of
polyvascular disease) are useful to predict the presence of HF in T2DM patients. Therefore,
we consider it necessary to perform a systematic screening of HF in T2DM patients who
meet these criteria to administer the appropriate treatment and improve the prognosis.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/jcm10204634/s1, Figure S1: Prevalence of HF type based on patients’ concomitant conditions,
Table S1: Patients’ baseline characteristics based on the type of HF.
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